Author(s):
Nitin S. Salve, Yash K. Chordia, Rushikesh P. Tikhe, Amol S. Bansode
Email(s):
amol.bansode12@gmail.com
DOI:
10.52711/2321-5836.2026.00027 
Address:
Nitin S. Salve, Yash K. Chordia, Rushikesh P. Tikhe, Amol S. Bansode*
Department of Pharmaceutical Chemistry, Sinhgad Institute of Pharmacy, Narhe, Pune 411041, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 2,
Year - 2026
ABSTRACT:
Quality Risk Management (QRM) has evolved from a compliance formality into a strategic, science-based framework governing pharmaceutical quality across the product lifecycle. Anchored in ICH Q9 (2005) and its 2023 revision ICH Q9(R1), QRM provides a systematic process for identifying, assessing, controlling, communicating, and reviewing risks to drug product quality and patient safety. This review examines the foundational principles, global regulatory frameworks, key amendments introduced by Q9(R1), risk assessment methodologies, lifecycle integration with ICH Q10 and Q12, comparative QRM in sterile and non-sterile manufacturing, digital transformation including artificial intelligence and predictive analytics, major industry failure case studies, and regulatory inspection trends from 2020 to 2025. Key themes include the shift from subjective scoring to evidence-based risk assessment, the principle of proportionality in formality, recognition of product availability as a patient safety concern, and the emergence of hybrid quantitative-qualitative risk models supported by digital quality systems. Regulatory inspection analysis highlights persistent systemic gaps in data integrity, change management risk assessment, supplier oversight, and operational connectivity of risk outputs. The review concludes by identifying research gaps in AI governance, supply chain risk intelligence, biologics risk profiling, and patient-centered risk metrics. QRM under ICH Q9(R1) is positioned as an indispensable strategic pillar for patient protection, regulatory flexibility, and continuous improvement throughout the pharmaceutical product lifecycle.
Cite this article:
Nitin S. Salve, Yash K. Chordia, Rushikesh P. Tikhe, Amol S. Bansode. Quality Risk Management (QRM) under ICH Q9(R1): Advanced Implementation Strategies, Regulatory Perspectives, and Lifecycle Integration in Pharmaceutical Manufacturing. Research Journal of Pharmacology and Pharmacodynamics.2026;18(2):197-4. doi: 10.52711/2321-5836.2026.00027
Cite(Electronic):
Nitin S. Salve, Yash K. Chordia, Rushikesh P. Tikhe, Amol S. Bansode. Quality Risk Management (QRM) under ICH Q9(R1): Advanced Implementation Strategies, Regulatory Perspectives, and Lifecycle Integration in Pharmaceutical Manufacturing. Research Journal of Pharmacology and Pharmacodynamics.2026;18(2):197-4. doi: 10.52711/2321-5836.2026.00027 Available on: https://www.rjppd.org/AbstractView.aspx?PID=2026-18-2-12
14. REFERENCES:
1. International Council for Harmonisation (ICH). ICH Harmonised Guideline Q9(R1): Quality Risk Management. Step 4 version. Geneva: ICH; 2023.
2. U.S. Food and Drug Administration. Guidance for Industry: Q9 Quality Risk Management. Silver Spring (MD): FDA; 2023. Available at: https://www.fda.gov
3. European Medicines Agency. ICH guideline Q9(R1) on quality risk management. Amsterdam: EMA; 2023. Available at: https://www.ema.europa.eu
4. World Health Organization. WHO Technical Report Series No. 1033, Annex 2: WHO guidelines on quality risk management. Geneva: WHO; 2021.
5. Pharmaceutical Inspection Co-operation Scheme (PIC/S). Guide to Good Manufacturing Practice for Medicinal Products PE 009-16. Geneva: PIC/S; 2022.
6. International Council for Harmonisation (ICH). ICH Harmonised Guideline Q8(R2): Pharmaceutical Development. Geneva: ICH; 2009.
7. U.S. Food and Drug Administration. FY 2023 Drug Quality Sampling and Testing Annual Report. Silver Spring (MD): FDA; 2024.
8. European Commission. EudraLex Volume 4, Annex 1: Manufacture of Sterile Medicinal Products (Revised). Brussels: European Commission; 2022.
9. International Society for Pharmaceutical Engineering (ISPE). Risk-Based Manufacture of Pharmaceutical Products (Risk-MaPP). North Bethesda (MD): ISPE; 2010.
10. U.S. Food and Drug Administration. Pharmaceutical cGMPs for the 21st Century — A Risk-Based Approach. Final Report. Silver Spring (MD): FDA; 2004.
11. International Organization for Standardization. ISO 31000:2018 Risk management — Guidelines. Geneva: ISO; 2018.
12. U.S. Food and Drug Administration, Office of Pharmaceutical Quality. OPQ Annual Report 2022. Silver Spring (MD): FDA; 2023.
13. European Medicines Agency. Annual Report 2023. Amsterdam: EMA; 2024.
14. Parenteral Drug Association. PDA Technical Report No. 54-2: Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations. Bethesda (MD): PDA; 2020.
15. Liu HC, Liu L, Liu N. Risk evaluation approaches in failure mode and effects analysis: A literature review. Expert Syst Appl. 2013;40(2):828–838. doi:10.1016/j.eswa.2012.08.010.
16. Kabir S, Papadopoulos Y. Applications of Bayesian networks and fuzzy logic in risk assessment: A review. Reliab Eng Syst Saf. 2019;187:57–73. doi:10.1016/j.ress.2019.02.003.
17. Organisation for Economic Co-operation and Development. Strengthening the resilience of global pharmaceutical supply chains. Paris: OECD Publishing; 2021.
18. Vesper JL. Risk assessment and risk management in pharmaceutical manufacturing. PDA J Pharm Sci Technol. 2011;65(3):337–345. doi:10.5731/pdajpst.2011.00789.
19. Stamatis DH. Failure mode and effect analysis: FMEA from theory to execution. 2nd ed. Milwaukee (WI): ASQ Quality Press; 2003.
20. Rathore AS, Winkle H. Risk-based approaches for lifecycle pharmaceutical quality management. J Pharm Innov. 2010; 5(4): 227–236. doi:10.1007/s12247-010-9096-0.
21. Aven T. Risk assessment and risk management: Review of recent advances on their foundation. Eur J Oper Res. 2016; 253(1): 1–13. doi:10.1016/j.ejor.2015.12.023.
22. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27(1):26–34. doi:10.1038/nbt0109-26.
23. Yu LX, Amidon G, Khan MA et al. Understanding pharmaceutical quality by design. AAPS J. 2014; 16(2): 771–783. doi:10.1208/s12248-014-9597-4.
24. International Council for Harmonisation (ICH). ICH Harmonised Guideline Q10: Pharmaceutical Quality System. Geneva: ICH; 2008.
25. McDermott RE, Mikulak RJ, Beauregard MR. The basics of FMEA. 3rd ed. Boca Raton (FL): CRC Press; 2019.
26. Sandle T. Risk management approaches for aseptic processing. PDA J Pharm Sci Technol. 2016;70(4):351–360. doi:10.5731/pdajpst.2016.006734.
27. Medicines and Healthcare products Regulatory Agency. GMP Inspection Deficiency Data 2021–2022. London: MHRA; 2022. Available at: https://www.gov.uk/mhra
28. International Council for Harmonisation (ICH). ICH Harmonised Guideline Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Geneva: ICH; 2019.
29. Sandle T. Environmental monitoring trends in pharmaceutical manufacturing. Eur J Parenter Pharm Sci. 2021;26(2):65–72.
30. International Council for Harmonisation (ICH). ICH Harmonised Guideline Q14: Analytical Procedure Development. Geneva: ICH; 2023.
31. Sandle T. Cleaning validation failures and contamination risk assessment. Pharm Technol Eur. 2019; 31(4): 24–29.
32. Lee SL, O'Connor TF, Yang X et al. Modernizing pharmaceutical manufacturing: From batch to continuous production. J Pharm Innov. 2015; 10(3): 191–199. doi:10.1007/s12247-015-9215-8.
33. Ierapetritou MG, Ramachandran R. Process analytical technology and digital transformation in pharmaceutical manufacturing. Comput Chem Eng. 2021; 147: 107252. doi:10.1016/j.compchemeng.2021.107252.
34. Choi TM, Wallace SW, Wang Y. Big data analytics in operations management. Prod Oper Manag. 2018; 27(10): 1868–1883. doi:10.1111/poms.12838.
35. Liu HC, Liu L, Liu N. Risk evaluation approaches in failure mode and effects analysis: A literature review. Expert Syst Appl. 2013; 40(2): 828–838.
36. Endsley MR. Toward a theory of situation awareness in dynamic systems. Hum Factors. 1995; 37(1): 32–64. doi:10.1518/001872095779049543.
37. Kusiak A. Smart manufacturing. Int J Prod Res. 2018; 56(1–2): 508–517. doi:10.1080/00207543.2017.1351644.
38. Yang Q, Liu Y, Chen T et al. Federated machine learning: Concept and applications. ACM Trans Intell Syst Technol. 2019; 10(2): 1–19. doi:10.1145/3298981.
39. Kuo TT, Kim HE, Ohno-Machado L. Blockchain distributed ledger technologies for biomedical and health care applications. J Am Med Inform Assoc. 2017; 24(6): 1211–1220. doi:10.1093/jamia/ocx068.
40. Sandle T. Risk management approaches for aseptic processing. PDA J Pharm Sci Technol. 2016; 70(4): 351–360.
41. Khan FI, Abbasi SA. Fault tree analysis: A review of methodologies. J Loss Prev Process Ind. 2001; 14(4): 299–318.
42. U.S. Food and Drug Administration. Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry. Silver Spring (MD): FDA; 2021.
43. Agalloco J, Akers J. Aseptic processing recalls and contamination investigations: Lessons learned. PDA J Pharm Sci Technol. 2018; 72(6): 567–575. doi:10.5731/pdajpst.2018.009345.
44. U.S. Food and Drug Administration. Data Integrity and Compliance With CGMP: Guidance for Industry. Silver Spring (MD): FDA; 2018.
45. Medicines and Healthcare products Regulatory Agency. GMP data integrity definitions and guidance for industry. London: MHRA; 2018.
46. Ivanov D. Supply chain viability and the COVID-19 pandemic. Int J Prod Res. 2021; 59(12): 3537–3550. doi:10.1080/00207543.2020.1750727.
47. Rathore AS, Sofer G. Technology transfer in biopharmaceutical manufacturing. Biotechnol Prog. 2005; 21(5): 1489–1496. doi:10.1021/bp050184w.
48. U.S. Food and Drug Administration. Warning Letters Database. Silver Spring (MD): FDA; 2024. Available at: https://www.fda.gov
49. European Medicines Agency. GMP/GDP Inspectors Working Group. Annual Report 2021. Amsterdam: EMA; 2022.
50. Medicines and Healthcare products Regulatory Agency. GMP Inspection Metrics Annual Report 2023. London: MHRA; 2024.
51. Pharmaceutical Quality Alliance. Risk Management Plan Template and Guidance. Arlington (VA): PQA; 2022.
52. Tang CS. Perspectives in supply chain risk management. Int J Prod Econ. 2006;103(2):451–488. doi:10.1016/j.ijpe.2005.12.006.
53. European Medicines Agency. Guideline on computerised systems and electronic data in clinical trials. Amsterdam: EMA; 2023.
54. Detert JR, Burris ER. Leadership behavior and employee voice: Is the door really open? Acad Manage J. 2007; 50(4): 869–884. doi:10.5465/amj.2007.26279183.
55. Floridi L, Cowls J, Beltrametti M et al. AI4People — An ethical framework for a good AI society. Minds Mach. 2018; 28(4): 689–707. doi:10.1007/s11023-018-9482-5.
56. Walsh G. Biopharmaceutical benchmarks 2022. Nat Biotechnol. 2022; 40(3): 363–372. doi:10.1038/s41587-022-01245-3.
57. Judge TA, Piccolo RF, Ilies R. The forgotten ones? The validity of consideration and initiating structure in leadership research. J Appl Psychol. 2004; 89(1): 36–51. doi:10.1037/0021-9010.89.1.36.
58. Black J. Risk-based regulation: Choices, practices and lessons being learnt. In: Risk and Regulatory Policy. Paris: OECD Publishing; 2010.
59. Hartmann J, Schmitt J, Reuss M. Linking pharmaceutical manufacturing quality to clinical outcomes. Pharmacoepidemiol Drug Saf. 2017; 26(7): 800–807. doi:10.1002/pds.4210.
60. Smith R, Rennie D. Continuing professional development in pharmaceutical quality systems. BMJ. 2014; 348: g314. doi:10.1136/bmj.g314.
61. ICH. ICH Q13 Guideline on Continuous Manufacturing of Drug Substances and Drug Products. Geneva: ICH; 2022.